A Review of CYP3A Drug-Drug Interaction Studies: Practical Guidelines for Patients Using Targeted Oral Anticancer Drugs

Many oral anticancer drugs are metabolized by CYP3A. Clinical drug-drug interaction (DDI) studies often only examine the effect of strong CYP3A inhibitors and inducers. The effect of moderate or weak inhibitors or inducers can be examined using physiologically based pharmacokinetic simulations, but...

Descripción completa

Detalles Bibliográficos
Autores principales: Molenaar-Kuijsten, Laura, Van Balen, Dorieke E. M., Beijnen, Jos H., Steeghs, Neeltje, Huitema, Alwin D. R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8435708/
https://www.ncbi.nlm.nih.gov/pubmed/34526892
http://dx.doi.org/10.3389/fphar.2021.670862

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8435708/
https://www.ncbi.nlm.nih.gov/pubmed/34526892
http://dx.doi.org/10.3389/fphar.2021.670862

Ejemplares similares